Arrowhead Pharmaceuticals, Inc.ARWRNASDAQ
Loading
Year-over-year free cash flow growth rate
Latest
-12.84%
↓ 111% vs avg
Percentile
P46
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
118.28%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -12.84% |
| Q3 2025 | 108.28% |
| Q2 2025 | -134.54% |
| Q1 2025 | 395.70% |
| Q4 2024 | 4.78% |
| Q3 2024 | -24.36% |
| Q2 2024 | -2.70% |
| Q1 2024 | 32.20% |
| Q4 2023 | -109.16% |
| Q3 2023 | -32.33% |
| Q2 2023 | -14.24% |
| Q1 2023 | 48.45% |
| Q4 2022 | -12.87% |
| Q3 2022 | -29.39% |
| Q2 2022 | -235.14% |
| Q1 2022 | 186.42% |
| Q4 2021 | -107.59% |
| Q3 2021 | 3.65% |
| Q2 2021 | -113.07% |
| Q1 2021 | 694.33% |
| Q4 2020 | -239.18% |
| Q3 2020 | 64.19% |
| Q2 2020 | -14.01% |
| Q1 2020 | -12.01% |
| Q4 2019 | -565.80% |
| Q3 2019 | -18.13% |
| Q2 2019 | 136.89% |
| Q1 2019 | -111.82% |
| Q4 2018 | 5042.70% |
| Q3 2018 | 76.79% |
| Q2 2018 | 7.68% |
| Q1 2018 | -6.72% |
| Q4 2017 | -59.23% |
| Q3 2017 | 19.51% |
| Q2 2017 | 26.24% |
| Q1 2017 | -433.42% |
| Q4 2016 | 136.48% |
| Q3 2016 | 32.13% |
| Q2 2016 | -28.00% |
| Q1 2016 | 31.14% |